The results of the ADVANCE-ON trial released at the ESC Congress in Barcelona and at the EASD Congress in Vienna demonstrated that strict blood pressure control diminished overall and cardiovascular death during that time. However, patients in the ADVANCE-ON follow-up study had no difference in outcomes whether their blood sugar was tightly regulated or not.

These effects depart with those seen in the long-term follow-up of the UKPDS trial, which found significant legacy effects for intense glycemic control but not for tight blood pressure control. It may partly be explained by patients in ADVANCE having more advanced diabetes and more pre-existing cardiovascular disease than those in UKPDS. In the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) factorial trial, the combination of perindopril and indapamide reduced mortality among patients with type 2 diabetes, but intensive glucose control, targeting a glycated hemoglobin level of less than 6.5%, did not. ADVANCE-ON report results of the 6-year post-trial follow-up.

Read More